COYA Financials Coya Therapeutics, Inc.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $8M | -$21M | 0.0% | -283.9% | -49.3% | -42.5% | — | — | $47M |
| 2024 | $4M | -$15M | 0.0% | -485.4% | -37.6% | -33.6% | — | — | $38M |
| 2023 | $6M | -$8M | 0.0% | -131.7% | -22.4% | -19.4% | — | — | $33M |
| 2022 | $0 | -$12M | — | — | 145.9% | -145.8% | — | — | $6M |
| 2021 | — | -$5M | — | — | -134.3% | -102.1% | — | — | $4M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $243745 | -$7M | 0.0% | -2891.1% | -15.3% | -14.0% | — | — | $43M |
| Mar '26 | $251147 | -$7M | 0.0% | -3042.1% | -14.7% | -13.5% | — | — | $51M |
| Dec '25 | $4M | -$6M | 0.0% | -152.3% | -13.3% | -11.4% | — | — | $47M |
| Sep '25 | $4M | -$2M | 0.0% | -68.3% | -7.8% | -6.6% | — | — | $28M |
| Jun '25 | $163616 | -$6M | 0.0% | -3920.5% | -21.5% | -18.2% | — | — | $30M |
| Mar '25 | $257884 | -$7M | 0.0% | -2976.9% | -21.9% | -19.0% | — | — | $36M |
| Dec '24 | $1952 | -$3M | 0.0% | -209031.5% | -7.4% | -6.6% | — | — | $38M |
| Sep '24 | $0 | -$4M | — | — | -12.6% | -11.3% | — | — | $31M |
| Jun '24 | $3M | -$3M | 0.0% | -94.5% | -8.2% | -7.2% | — | — | $37M |
| Mar '24 | $126838 | -$5M | 0.0% | -4322.8% | -15.6% | -13.5% | — | — | $36M |
| Dec '23 | $6M | $1M | 0.0% | 30.2% | 3.6% | 3.1% | — | — | $33M |
| Sep '23 | $0 | -$3M | — | — | -33.9% | -28.8% | — | — | $11M |
| Jun '23 | $0 | -$3M | — | — | -23.4% | -21.4% | — | — | $13M |
| Mar '23 | $0 | -$3M | — | — | -16.9% | -15.7% | — | — | $16M |
| Dec '22 | — | -$3M | — | — | 37.0% | -37.0% | — | — | $6M |
| Sep '22 | — | -$4M | — | — | 75.1% | — | — | — | — |
| Jun '22 | — | -$3M | — | — | 242.7% | — | — | — | — |
| Mar '22 | — | -$2M | — | — | -86.8% | — | — | — | — |
Valuation over time
How the market has priced COYA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 23.1× (Jan '24) to 9.5× (Nov '26).
Frequently asked questions
Is COYA growing its revenue and profit?
See the revenue and net-income charts above for Coya Therapeutics, Inc.'s multi-year trend.
How much debt does COYA have?
As of FY2025, Coya Therapeutics, Inc. reported — of total debt against $47M of cash.
What is COYA's profit margin?
In FY2025, gross margin was —, operating margin -283.9%, and net margin -267.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.